Marshall Wace LLP Makes New $390,000 Investment in LENZ Therapeutics, Inc. (NASDAQ:LENZ)

Marshall Wace LLP purchased a new stake in shares of LENZ Therapeutics, Inc. (NASDAQ:LENZ) during the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm purchased 22,554 shares of the company’s stock, valued at approximately $390,000. Marshall Wace LLP owned 0.62% of LENZ Therapeutics at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently made changes to their positions in LENZ. RA Capital Management L.P. bought a new stake in shares of LENZ Therapeutics in the 1st quarter valued at about $93,313,000. Vanguard Group Inc. bought a new stake in LENZ Therapeutics during the 1st quarter valued at $4,621,000. Jennison Associates LLC purchased a new position in shares of LENZ Therapeutics in the 1st quarter valued at $3,009,000. Ikarian Capital LLC bought a new position in shares of LENZ Therapeutics in the 1st quarter worth $1,898,000. Finally, Wealth Enhancement Advisory Services LLC purchased a new stake in shares of LENZ Therapeutics during the 2nd quarter worth $1,437,000. 54.32% of the stock is currently owned by institutional investors.

LENZ Therapeutics Stock Down 3.5 %

NASDAQ LENZ opened at $23.60 on Friday. LENZ Therapeutics, Inc. has a 12-month low of $14.07 and a 12-month high of $29.82. The company has a fifty day simple moving average of $22.87 and a two-hundred day simple moving average of $20.04.

LENZ Therapeutics (NASDAQ:LENZ) last issued its quarterly earnings results on Wednesday, August 14th. The company reported ($0.40) EPS for the quarter, topping analysts’ consensus estimates of ($0.49) by $0.09. On average, research analysts expect that LENZ Therapeutics, Inc. will post -2.81 earnings per share for the current year.

Wall Street Analyst Weigh In

Several equities analysts have issued reports on LENZ shares. HC Wainwright began coverage on LENZ Therapeutics in a research note on Monday, August 12th. They issued a “buy” rating and a $38.00 target price on the stock. Piper Sandler reissued an “overweight” rating and set a $36.00 target price on shares of LENZ Therapeutics in a research report on Thursday, August 15th. William Blair raised shares of LENZ Therapeutics to a “strong-buy” rating in a report on Friday, August 30th. Finally, Raymond James began coverage on LENZ Therapeutics in a report on Friday, September 27th. They set an “outperform” rating and a $37.00 price objective for the company. Six investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Buy” and a consensus price target of $35.40.

LENZ Therapeutics Profile

LENZ Therapeutics, Inc, a biopharmaceutical company, focuses on developing and commercializing therapies to improve vision in the United States. Its product candidates include LNZ100 and LNZ101 which are in Phase III clinical trials for the treatment of presbyopia. The company is headquartered in Del Mar, California.